Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 3Phase 1 3Phase 3 2Phase EARLY_PHASE1 1

Status

Completed 3Unknown 2Recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Resectable Pancreatic Cancer 1Pancreatic Neoplasms 1

Interventions

Carboplatin 98Cisplatin 95pembrolizumab 90Gemcitabine 81Paclitaxel 80Docetaxel 73Capecitabine 64Oxaliplatin 53Specimen Handling 52Fluorouracil 52Magnetic Resonance Spectroscopy 50Bevacizumab 49Radiotherapy 48Dexamethasone 45Cyclophosphamide 44Leucovorin 39Drug Therapy 39Irinotecan 37Doxorubicin 36Pemetrexed 35Injections 30Trastuzumab 28Vincristine 27Rituximab 27Radiosurgery 25Prednisone 25Etoposide 25130-nm albumin-bound paclitaxel 25Radiation 24Letrozole 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × folfirinox × Clear all
NCT06714604 2024-12-03

ADVANTAGE

Sahlgrenska University Hospital

Phase 3 Recruiting
432 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05529940 2024-11-27

NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)

Seoul National University Hospital

Phase 3 Recruiting
609 enrolled
Gastrointestinal

Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡